Oppenheimer raised the firm’s price target on HCA Healthcare (HCA) to $400 from $390 and keeps an Outperform rating on the shares. The firm notes HCA’s Q3 results overcame the adverse effects of the hurricanes, which will continue into Q4 and push FY2024 guidance to the low end of the range. Despite continued hurricane-related headwinds, management expects 2025 earnings growth at or above its long-term target, underpinned by above-trend admissions growth of 3%-4%.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $440 from $450 at TD Cowen
- HCA Healthcare price target lowered to $406 from $427 at Morgan Stanley
- HCA Healthcare price target lowered to $420 from $475 at KeyBanc
- Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz
- Morning Movers: Capri sinks after judge blocks planned takeover by Tapestry